Black Diamond Therapeutics, Inc. (BDTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Black Diamond Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Black Diamond Therapeutics, Inc. (BDTX) has returned -12.35% so far this year and 37.42% over the past 12 months.

Based on dividend-adjusted daily data since Jan 30, 2020, BDTX's average daily return is +0.01%, while the average monthly return is +0.05%. At this rate, your investment would double in approximately 115.6 years.

Historically, 44% of months were positive and 56% were negative. The best month was Jun 2023 with a return of +171.5%, while the worst month was May 2021 at -50.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.

On a daily basis, BDTX closed higher 45% of trading days. The best single day was Jun 27, 2023 with a return of +235.9%, while the worst single day was May 20, 2021 at -37.3%.

Black Diamond Therapeutics, Inc. has an annualized alpha of -14.20%, beta of 1.37, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 31, 2020.

• This stock participated in 222.97% of S&P 500 Index downside but only 118.59% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BDTX ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Black Diamond Therapeutics, Inc. (BDTX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Black Diamond Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Black Diamond Therapeutics, Inc. was 97.21%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Black Diamond Therapeutics, Inc. drawdown is 95.25%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Black Diamond Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Black Diamond Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.